A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery
A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery
批准号:
10161750
负责人:
Gary D Luker
金额:
$36.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-05-31
关键词:
3-DimensionalAddressAnimalsAntineoplastic AgentsBiological ModelsBiopolymersBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineCarcinomaCellsCoculture TechniquesColorCombined Modality TherapyComplexDevicesDisease modelDropsDrug ScreeningDrug resistanceEngineeringEnvironmentEpithelialEventExtracellular MatrixFibroblastsGrowthHumanImmersionIn VitroIndustrializationMalignant NeoplasmsMammary NeoplasmsMediatingMicrofluidic MicrochipsModelingMolecularMusNeoplasm MetastasisOutcomePathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacotherapyPhasePhysiologicalPolymersPrimary Cell CulturesPropertyProteinsReproducibilityResearchResistanceRoboticsSignal PathwaySignal TransductionSpeedStromal CellsStromal NeoplasmSystemTechniquesTechnologyTestingTissuesTreatment EfficacyVariantXenograft Modelangiogenesisaqueousbasebioluminescence imagingcancer cellcancer drug resistancecancer therapychemotherapycombinatorialdesigndrug developmentdrug discoverydrug sensitivitydrug testingdrug use screeningeffective therapyeffectiveness validationflexibilityhigh throughput screeninghigh throughput technologyhigh-throughput drug screeninghuman modelimprovedimproved outcomein vivoinhibitor/antagonistmalignant breast neoplasmmechanical propertiesmouse modelnew technologynoveloperationpatient derived xenograft modelpersonalized cancer therapyphysiologic modelprecision drugsprecision medicineprecision oncologyresponsesmall moleculethree dimensional cell culturetooltriple-negative invasive breast carcinomatumortumor growthtumor progression
中文摘要
项目摘要
肿瘤间质,包括细胞外基质(ECM)和细胞,基本上调节所有方面的
肿瘤的生长和转移。肿瘤中癌细胞、间质细胞和细胞外基质之间的信号转导促进
除其他关键结果外,还包括癌细胞的增殖和耐药性。因此,破坏基质-
癌细胞信号转导对恢复癌细胞的药物敏感性和改善预后至关重要
病人。尽管认识到这一点,但缺乏生理学的、高通量的人类肿瘤模型
阻碍针对肿瘤-间质相互作用的药物开发和发现努力。
我们将通过开发高通量肿瘤微组织技术来满足这一需求,以重建
此外,我们还研究了天然肿瘤的复杂性,并实现了针对肿瘤间质信号的药物测试。这种轻便的技术
基于用户定义的癌细胞、间质细胞和ECM的两步机器人微图案化,使用
1536微孔板中的聚合物双水相体系。癌细胞的3D团块形成于
纳米水滴沉淀在微孔的底部,与浸泡的水相不相容。
然后分配含有基质成分的第二水滴以与纳米滴合并
并包围癌细胞块,以在孵育时自发产生微组织。这种方法
独一无二地提供了将组织特定的基质蛋白和不同的基质细胞整合到
在体内复制肿瘤的物理化学性质。我们将使用三重负片来验证这项技术
乳腺癌(TNBC)作为疾病模型,显示肿瘤相关成纤维细胞(CAF)的作用
ECM对癌细胞增殖和药物反应的影响。有了这项技术,我们将测试
干扰肿瘤间质信号对TNBC细胞治疗效果的影响。这些研究将使用
TNBC细胞系和条件重编程细胞的工程化肿瘤模型
建立我们的TMT模型系统用于治疗转移性TNBC患者癌细胞的可行性
精确肿瘤学。我们将使用标准化疗药物进行联合药物筛选,并
抗信号通路的分子抑制剂激活在特定的TNBC患者的细胞中以抑制间质-
介导癌细胞增殖和耐药性,并在小鼠身上验证最有效的治疗方法
人TNBC异种移植模型的建立。通过这项研究,我们希望将我们的TMT技术作为一种
将广泛应用于药物发现、乳房机制研究的变革性进展
癌症和其他恶性肿瘤,以及精准医学。
英文摘要
Project Summary
Tumor stroma, encompassing both extracellular matrix (ECM) and cells, regulates essentially all aspects of
tumor growth and metastasis. Signaling among cancer cells, stromal cells, and ECM in tumors promotes
proliferation of cancer cells and drug resistance among other key outcomes. Therefore, disrupting stroma-
cancer cells signaling is essential to restoring drug sensitivity of cancer cells and improving outcomes for
patients. Despite this recognition, the lack of physiologic, high throughput human tumors models significantly
impedes drug development and discovery efforts targeting tumor-stromal interactions.
We will address this need by developing a high throughput tumor microtissue technology to recreate the
complexity of native tumors and enable drug testing against tumor-stromal signaling. This facile technology
is based on two-step robotic micropatterning of user-defined cancer cells, stromal cells, and ECM using a
polymeric aqueous two-phase system in 1536 microwell plates. A 3D mass of cancer cells is formed in an
aqueous nanodrop settled at the bottom of a microwell and immiscible from the immersion aqueous phase.
A second aqueous drop containing the stromal components is then dispensed to merge with the nanodrop
and surround the cancer cell mass to spontaneously generate a microtissue upon incubation. This approach
uniquely offers the flexibility of incorporating tissue-specific matrix proteins and different stromal cells to
reproduce physicochemical properties of tumors in vivo. We will validate this technology using triple negative
breast cancer (TNBC) as a disease model, demonstrating effects of carcinoma-associated fibroblasts (CAFs)
and ECM on proliferation and drug responses of cancer cells. With this technology, we will test effects of
disrupting tumor-stromal signaling on treatment efficacy against TNBC cells. These studies will use
engineered tumor models of both TNBC cell lines and conditionally reprogrammed cells generated from
cancer cells of patients with metastatic TNBC to establish the feasibility of using our TMT model system for
precision oncology. We will perform combinatorial drug screening using standard chemotherapeutics and
molecular inhibitors against signaling pathways active in cells of specific TNBC patients to inhibit stroma-
mediated proliferation and drug resistance of cancer cells, and validate the most effective treatments in mouse
xenograft models of human TNBC. Through this research, we expect to establish our TMT technology as a
transformative advance that will be implemented broadly for drug discovery, mechanistic studies of breast
cancer and other malignancies, and precision medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Imaging Tools for Intercellular Chemokine Signalling
-
批准号:10706896
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2023
-
负责人:Gary D Luker
-
依托单位:
Imaging Disease Heterogeneity and Response to Therapy in Myelofibrosis
-
批准号:10360496
-
项目类别:
-
资助金额:$60.82万
-
财政年份:2019
-
负责人:Gary D Luker
-
依托单位:
Imaging Disease Heterogeneity and Response to Therapy in Myelofibrosis
-
批准号:9891988
-
项目类别:
-
资助金额:$62.07万
-
财政年份:2019
-
负责人:Gary D Luker
-
依托单位:
Imaging Disease Heterogeneity and Response to Therapy in Myelofibrosis
-
批准号:10563197
-
项目类别:
-
资助金额:$60.82万
-
财政年份:2019
-
负责人:Gary D Luker
-
依托单位:
A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery
-
批准号:10337608
-
项目类别:
-
资助金额:$5.92万
-
财政年份:2019
-
负责人:Gary D Luker
-
依托单位:
A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery
-
批准号:10330116
-
项目类别:
-
资助金额:$16.64万
-
财政年份:2019
-
负责人:Gary D Luker
-
依托单位:
A Novel High Throughput Tumor Spheroid Microtechnology
-
批准号:8625056
-
项目类别:
-
资助金额:$25.75万
-
财政年份:2013
-
负责人:Gary D Luker
-
依托单位:
A Novel High Throughput Tumor Spheroid Microtechnology
-
批准号:8738627
-
项目类别:
-
资助金额:$24.57万
-
财政年份:2013
-
负责人:Gary D Luker
-
依托单位:
Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)
-
批准号:8704735
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2012
-
负责人:Gary D Luker
-
依托单位:
Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)
-
批准号:8532861
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2012
-
负责人:Gary D Luker
-
依托单位:
Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)
-
批准号:8374192
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2012
-
负责人:Gary D Luker
-
依托单位:
Olympus FV1000-MPE Confocal & Multi-Photon Imaging System
-
批准号:7834613
-
项目类别:
-
资助金额:$93.96万
-
财政年份:2010
-
负责人:Gary D Luker
-
依托单位:
Microfluidic Models of Metastatic Cancer
-
批准号:8015364
-
项目类别:
-
资助金额:$30.22万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Molecular Imaging of Chemokine Receptor Signaling
-
批准号:8204602
-
项目类别:
-
资助金额:$30.24万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Microfluidic Models of Metastatic Cancer
-
批准号:8215885
-
项目类别:
-
资助金额:$30.41万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Molecular Imaging of Chemokine Receptor Signaling
-
批准号:8387781
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Molecular Imaging of Chemokine Receptor Signaling
-
批准号:7563656
-
项目类别:
-
资助金额:$31.25万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Molecular Imaging of Chemokine Receptor Signaling
-
批准号:7991369
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Microfluidic Models of Metastatic Cancer
-
批准号:8458895
-
项目类别:
-
资助金额:$28.55万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
Microfluidic Models of Metastatic Cancer
-
批准号:7649893
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2009
-
负责人:Gary D Luker
-
依托单位:
海外基金